Table 3.
Regression of TKV normalized to BSA on serum markers of endothelial dysfunction and oxidative stress/inflammation
| Variable | Model | Estimate ± SE | P Value |
|---|---|---|---|
| ADMA | Unadjusted | 435.27 ± 188.86 | 0.0247 |
| Model 1 | 450.36 ± 192.95 | 0.0231 | |
| Model 2 | 402.56 ± 216.08 | 0.0679 | |
| Model 3 | 395.41 ± 196.38 | 0.0490 | |
| Arginine | Unadjusted | 116.03 ± 140.84 | 0.4134 |
| Model 1 | 120.79 ± 142.55 | 0.4004 | |
| Model 2 | 72.69 ± 149.20 | 0.6281 | |
| Model 3 | 47.79 ± 147.38 | 0.7470 | |
| Cysteine | Unadjusted | 264.37 ± 125.79 | 0.0399 |
| Model 1 | 258.47 ± 134.75 | 0.0601 | |
| Model 2 | 253.75 ± 138.00 | 0.0714 | |
| Model 3 | 247.73 ± 134.13 | 0.0701 | |
| Glutathione | Unadjusted | −25.23 ± 37.05 | 0.4985 |
| Model 1 | −28.69 ± 37.66 | 0.4493 | |
| Model 2 | −25.65 ± 38.65 | 0.5097 | |
| Model 3 | −18.73 ± 37.94 | 0.6235 | |
| Homocysteine | Unadjusted | 264.37 ± 125.79 | 0.0399 |
| Model 1 | 258.47 ± 134.75 | 0.0601 | |
| Model 2 | 253.75 ± 138.00 | 0.0714 | |
| Model 3 | 247.73 ± 134.13 | 0.0701 | |
| Methionine | Unadjusted | 81.30 ± 128.50 | 0.5294 |
| Model 1 | 90.17 ± 130.65 | 0.4929 | |
| Model 2 | 113.19 ± 131.75 | 0.3941 | |
| Model 3 | 113.16 ± 130.68 | 0.3903 | |
| PGD2 | Unadjusted | 76.71 ± 69.42 | 0.2743 |
| Model 1 | 76.05 ± 69.96 | 0.2823 | |
| Model 2 | 69.57 ± 72.85 | 0.3446 | |
| Model 3 | 70.90 ± 71.09 | 0.3237 | |
| PGE2 | Unadjusted | 167.31 ± 79.49 | 0.0403 |
| Model 1 | 179.80 ± 80.00 | 0.0291 | |
| Model 2 | 157.56 ± 83.70 | 0.0661 | |
| Model 3 | 158.65 ± 82.83 | 0.0615 | |
| PGF2α | Unadjusted | 215.49 ± 67.27 | 0.0023 |
| Model 1 | 230.82 ± 66.69 | 0.0011 | |
| Model 2 | 218.22 ± 72.96 | 0.0045 | |
| Model 3 | 222.40 ± 73.03 | 0.0038 | |
| 8-Isoprostane | Unadjusted | 197.94 ± 65.84 | 0.0041 |
| Model 1 | 213.53 ± 65.41 | 0.0020 | |
| Model 2 | 201.05 ± 70.67 | 0.0066 | |
| Model 3 | 200.57 ± 69.99 | 0.0062 | |
| SAH | Unadjusted | 242.65 ± 203.38 | 0.2377 |
| Model 1 | 223.81 ± 204.90 | 0.2794 | |
| Model 2 | 162.72 ± 209.17 | 0.4401 | |
| Model 3 | 142.82 ± 206.38 | 0.4919 | |
| SAM | Unadjusted | −145.54 ± 134.07 | 0.2824 |
| Model 1 | −146.79 ± 134.45 | 0.2799 | |
| Model 2 | −228.93 ± 139.94 | 0.1081 | |
| Model 3 | −238.90 ± 137.92 | 0.0893 | |
| SAM/SAH ratio | Unadjusted | −214.94 ± 120.27 | 0.0794 |
| Model 1 | −213.20 ± 120.52 | 0.0827 | |
| Model 2 | −250.84 ± 120.01 | 0.0417 | |
| Model 3 | −253.75 ± 118.73 | 0.0374 | |
| SDMA | Unadjusted | 285.98 ± 102.69 | 0.0072 |
| Model 1 | 277.88 ± 104.14 | 0.0099 | |
| Model 2 | 235.48 ± 115.98 | 0.0473 | |
| Model 3 | 236.54 ± 113.84 | 0.0424 |
Values are estimate ± SE. Four models were run for each marker: 1) unadjusted; 2) model 1, adjusted for age and sex; 3) model 2, adjusted for age, sex, systolic BP, and ln-transformed serum creatinine; and 4) model 3, adjusted for age, sex, systolic BP, and ln-transformed eGFR. P value <0.05 was considered significant and is marked in bold. The variables were ln-transformed before analysis.